We’re getting ever closer to besting a frequent microscopic source of misery: the respiratory syncytial virus. Late Tuesday, Moderna announced the seemingly successful Phase III trial results of its experimental RSV vaccine. In older adults, the vaccine appeared to be over 80% effective at preventing two or more…
Read more…
Source : An RSV Vaccine From Moderna Passes Phase III Trial Amid Viral Surge
